The retinal research team has made new advances in the early detection of glaucoma visual damage

Glaucoma is the world's first irreversible blinding eye disease, with hidden onset, difficult early diagnosis, irreversible visual damage and other characteristics, so it is often called "thief who steals light"
.
Even so, if early detection and early intervention can effectively block or delay the progression of glaucoma, patients will be able to maximize the preservation of useful vision and maintain normal life and work
.

The research of new technologies for early diagnosis of glaucoma has always been a hot spot
in the world.
Recently, Professor Wang Zhongfeng, Institute of Brain Sciences/State Key Laboratory of Medical Neurobiology, Fudan University, and Professor Wu Jihong, Department of Ophthalmology, Affiliated Eye, Ear, Nose and Throat Hospital, after more than 3 years of cooperation, have made new progress in the early monitoring of glaucoma visual damage markers, and the research results are based on "A novel biosensing platform for detection of glaucoma biomarker GDF15 via an" integrated BLI-ELASA strategy" was published online in
the journal Biomaterials.

Accurate detection of the biomarker GDF15 will aid in glaucoma risk screening, early diagnosis, and progression assessment
.
In this study, using aptamer as a specific molecular recognition tool, an automated, high-throughput and real-time monitoring BLI-ELASA biosensing platform
was developed by combining the advantages of BLI technology and enzyme-linked aptamer sandwich assay (ELASA).
The platform has shown a high degree of accuracy and effectiveness in the detection and verification of clinical patient samples, providing a promising translational application tool
for the early detection, early diagnosis and early treatment of glaucoma.

Over the years, the Retinal Laboratory of the Institute of Brain Science, Fudan University, led by Academician Yang Xiongli, and the Glaucoma Group of the Affiliated Eye, Ear, Nose and Throat Hospital, led by Professor Sun Xinghuai, have focused on the combination
of basic research and clinical transformation.
They highly believe that joint research needs to find problems from clinical practice, solve problems in basic research, and then return to clinical transformation and application, so as to benefit patients
with eye diseases in China.
The results were mainly jointly completed by Gao Shunxiang, a doctoral student of the Academy of Brain Sciences, and Dr.
Li Qian, of the Affiliated Eye, Ear, Nose and Throat Hospital, and Professor Wu Jihong and Professor Wang Zhongfeng were the co-corresponding authors
of the paper.
The research was funded
by the Ministry of Science and Technology of the People's Republic of China, the National Natural Science Foundation of China, the Shanghai Municipal Science and Technology Commission, the Shanghai Municipal Health Commission, and the Zhangjiang Laboratory.